GlassScriptPhysician profile
Benny M Popwell
NPI 1891799607
$4,238.39
in general payments reported to CMS, 2019-2025
34 companies · $589 in 2025
The $589 reported for 2025 was more than what 84% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $634 · 2020: $332 · 2021: $606 · 2022: $712 · 2023: $929 · 2024: $437 · 2025: $589.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,954.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,953.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,101.89 | 2019-2025 | |
| Exeltis, USA INC. | $395.36 | 2021-2025 | Slynd, Solosec |
| Pfizer INC. | $378.48 | 2019-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $260.07 | 2021-2025 | |
| Avion Pharmaceuticals | $230.30 | 2019-2023 | Balcoltra |
| Sumitomo Pharma America, INC. | $229.52 | 2023-2025 | Myfembree |
| Astellas Pharma US INC | $226.61 | 2020-2025 | Veozah |
| Evofem Biosciences, INC. | $153.45 | 2021-2025 | Phexxi, Solosec, Phexx |
| Sage Therapeutics, LLC | $147.29 | 2021-2025 | Zurzuvae |
| Hologic Sales and Service, LLC | $146.72 | 2023-2025 | Myosure Tissue Removal Device, Novasure, Omni Hysteroscope |
| Lupin INC. | $130.47 | 2019-2021 | |
| Mayne Pharma Commercial LLC | $97.21 | 2023-2025 | |
| Aspira Women'S Health INC | $71.10 | 2021 | |
| Lilly USA, LLC | $68.25 | 2019-2020 | |
| Millicent US INC | $56.77 | 2024-2025 | Intrarosa, Femring, Femlyv |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $53.89 | 2025 | Qelbree |
| Daiichi Sankyo INC. | $46.97 | 2019-2020 | |
| Therapeuticsmd, INC. | $45.75 | 2020-2021 | |
| Amgen INC. | $40.84 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $37.43 | 2019-2020 | |
| Shield Therapeutics INC | $35.84 | 2024 | |
| Medtronic, INC. | $34.65 | 2025 | Ligasure |
| Amag Pharmaceuticals, INC. | $33.53 | 2019 | |
| Duchesnay USA Incorporated | $28.82 | 2019 | |
| Welch Allyn | $24.97 | 2021 | |
| Becton, Dickinson and Company | $21.99 | 2025 | Bd Onclarity |
| Pacira Pharmaceuticals Incorporated | $20.08 | 2024 | Exparel |
| Scynexis, INC. | $20.01 | 2022 | |
| Axonics, INC. | $19.33 | 2023 | Axonics |
| Organon LLC | $17.81 | 2024 | |
| Smith+Nephew, INC. | $17.21 | 2025 | Pico |
| Takeda Pharmaceuticals U.S.A., INC. | $16.60 | 2022 | |
| Novo Nordisk INC | $16.35 | 2024 | Wegovy |
| Sanara Medtech INC. | $12.83 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benny Popwell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.